Vaxart (NASDAQ:VXRT) Bolsa

Vaxart

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart Inc

Citigroup analyst Geoff Meacham initiates coverage on Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Buy rating and announces Price Target of $72.

News

Price Target

Initiation

Analyst Ratings

PTGX

Citigroup Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $72

Citigroup analyst Geoff Meacham initiates coverage on NewAmsterdam Pharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) with a Buy rating and announces Price Target of $42.

NAMS

Citigroup Initiates Coverage On NewAmsterdam Pharma Co with Buy Rating, Announces Price Target of $42

Citigroup analyst Geoff Meacham initiates coverage on Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Buy rating and announces Price Target of $110.

ACLX

Citigroup Initiates Coverage On Arcellx with Buy Rating, Announces Price Target of $110

Citigroup analyst Geoff Meacham initiates coverage on Amylyx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) with a Buy rating and announces Price Target of $12.

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Citigroup Initiates Coverage On Amylyx Pharmaceuticals with Buy Rating, Announces Price Target of $12

Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces entering into a 50:50 joint venture with Mind Medicine Australia ("MMA") to operate a psychedelic-assisted therapies services clinic in Melbourne.
Incannex CEO Joel Latham commented, "This joint venture is a significant milestone around our strategy to bring psychedelic-assisted therapies to those who need them most. Working alongside a leading organization in this space, we expect to build the clinical infrastructure necessary to deliver safe, effective, and scalable treatment options. Importantly, this initiative not only strengthens our presence in a high-growth therapeutic sector but also aligns with our long-term commitment to generating opportunities for sustainable long-term shareholder value."
The new entity, Mind Medicine Australia Clinics, represents a strategic advancement in Incannex's commercialization model. The joint venture will deliver a fully integrated suite of services including clinical operations, governance, medicine supply, medical oversight, and marketing support to a growing network of aligned Authorised Prescribers across Australia.
Mind Medicine Australia Chairman Peter Hunt commented, "This groundbreaking initiative in partnership with Incannex brings critical resources and clinical expertise that will enhance the quality, accessibility, and scale of these transformative treatments. Our new clinic will serve as a Centre of Excellence, delivering best-in-class care and clinician training."
The updated clinic model will significantly expand treatment access by reducing the cost of entry and more than tripling capacity. These improvements are expected to benefit individuals suffering from post-traumatic stress disorder (PTSD), treatment-resistant depression, and other complex mental health conditions. Patient intake is expected to begin shortly in response to strong early demand.

IXHL

Incannex Launches Psychedelic Therapy Clinic in Australia to Expand Mental Health Treatment Access

Unlike one-dimensional AI agents, Mpower Agents are uniquely built to work across the entire enterprise – front, middle and back office – to automate complete journeys, not just conversations
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nice.com&amp;esheet=54276733&amp;newsitemid=20250617282648&amp;lan=en-US&amp;anchor=NiCE&amp;index=1&amp;md5=cbe08caca9865354f914dbea1223a7d9">NiCE</a> (NASDAQ:<a href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) today announced the launch of CXone Mpower Agents, a groundbreaking innovation that enables fully automated, AI agents to be created and deployed in seconds and immediately work across the customer service ecosystem – from self-service to mid-office approvals to back-end fulfillment. Mpower Agents make use of CXone Mpower's proprietary CX AI models, trained on rich use case-specific data and optimized workflows based on the actions of the best employees. They actively move across systems, trigger actions and work together with humans and other AI agents to automate entire service workflows.

NICE

NiCE Launches CXone Mpower Agents, Enabling Instant AI Deployment Across Customer Service

Needham analyst Laura Martin reiterates DoubleVerify Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Buy and maintains $18 price target.

Reiteration

Needham Reiterates Buy on DoubleVerify Holdings, Maintains $18 Price Target

Citigroup analyst Geoff Meacham initiates coverage on Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) with a Buy rating and announces Price Target of $4.

ABOS

Citigroup Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $4

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States
Study shows &gt;95% success rate, validating BE-Smart for use with esophageal brush cytology.
ProPhase Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced the successful completion of a key validation study evaluating the performance of the BE-Smart&#x2122; molecular diagnostic test compatibility with samples obtained from esophageal brush cytology. The study demonstrated BE-Smart&#x2122; achieved greater than a 95% technical success rate, confirming the BE-Smart's ability to reliably and accurately detect our panel of biomarkers, designed to assess progression risk in Barrett's esophagus and other distal esophageal conditions. Prophase will now move to accelerated commercialization of BE-Smart&#x2122; with expected clinical launch in the next 2-3 quarters.
BE-Smart uses a proprietary panel of biomarkers and a multi-modal analysis method which together significantly increase detection of deadly cancer cells in one of the fastest growing cancer indications, esophageal denocarcinoma cancer or "EAC". EAC has a 5-year mortality rate of over 79% and surged in annual incidence over 750% since the 1970s. BE-Smart represents a technical advance in detection and prognosis which has the potential to change cost and outcomes for the large population affected by GERD, Barrett's and EAC globally.

PRPH

ProPhase Labs Validates BE-Smart Test; Study Demonstrates High Accuracy; Clinical Rollout Expected Within 2-3 Quarters

<a href="https://pr.report/bkw9">SideChannel, Inc.</a> (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/SDCH#OTCQB">SDCH</a>) ("SideChannel"), a leader in modern cybersecurity technology and services solutions, today announced the deployment of its Enclave zero trust software by a second service branch of the United States Department of Defense ("DoD"). The engagement, facilitated through one of SideChannel's federal resale partners, represents a key validation of Enclave's ability to meet the large scale and strict cybersecurity needs of national security environments.
The deployment includes over 5,000 Enclave agents operating on-premise within national intelligence networks. The primary use cases are asset intelligence and certificate management - two critical areas for maintaining integrity and security control in sensitive infrastructure.

SDCH

SideChannel's Cybersecurity Tool Deployed by Second US Military Branch to Boost National Defense

A2Z Cust2Mate Secures $25M Order For 3,000 Smart Carts From Trixo For Major Latin American Retail Rollout Starting 2026

RDZN

Roadzen Inks Pact With Global Energy Giant SHV Energy's Indian Subsidiary, SUPERGAS, To Deploy AI-Powered ADAS Across Its LPG Fleet

John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) is looking for FY2026 Adj EPS of $3.90-$4.35 vs $3.80 analyst estimate..

Guidance

John Wiley & Sons Sees FY2026 Adj EPS $3.90-$4.35 vs $3.80 Est

Citigroup analyst Geoff Meacham initiates coverage on Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Sell rating and announces Price Target of $6.

NVAX

Citigroup Initiates Coverage On Novavax with Sell Rating, Announces Price Target of $6

SYRE

Spyre Therapeutics Announces Interim Phase 1 Results For Two Next-Generation TL1A Antibody Programs, And Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

<ul>
<li>Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models to identify which patients are most likely to benefit from BOT/BAL treatment</li>
<li>Collaboration builds on landmark 2024 Cancer Discovery study elucidating botensilimab's unique FcγR-mediated immune activation underlying activity in refractory tumors</li>
<li>Supports AI-enabled biomarker discovery, aligning with the national priorities and the FDA to expand access to personalized cancer treatment</li>
</ul>
Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>), a leader in immuno-oncology innovation, and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to Agenus' lead clinical stage immuno-oncology (IO) combination, botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1). The collaboration harnesses Noetik's proprietary virtual cell foundation models and large-scale, multimodal tumor data to uncover novel insights into the biology of tumor immunology. Together, the teams will deploy Noetik's first-in-class foundation models directly on clinical results with the aim to enrich clinical efficacy.

AGEN

Agenus Announces Research Collaboration To Develop Predictive Biomarkers Of Response To Clinical Stage IO Combination, Botensilimab

AerCap And AFI KLM E&M To Form LEAP Engine Leasing JV To Support Global A320neo And 737 MAX Operations

John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) reported quarterly earnings of $1.37 per share which beat the analyst consensus estimate of $1.27 by 7.87 percent. This is a 13.22 percent increase over earnings of $1.21 per share from the same period last year. The company reported quarterly sales of $442.58 million which beat the analyst consensus estimate of $434.90 million by 1.77 percent. This is a 5.52 percent decrease over sales of $468.46 million the same period last year.

Earnings

Earnings Beats

John Wiley & Sons Q4 Adj. EPS $1.37 Beats $1.27 Estimate, Sales $442.58M Beat $434.90M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) with a Buy rating and announces Price Target of $6.

GALT

HC Wainwright & Co. Assumes Galectin Therapeutics at Buy, Announces Price Target of $6

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) has edged past Elon Musk's EV giant in global sales for the first time, according to the International Council on Clean Transportation or ICCT.
What Happened: Chinese automakers are "building significant leads in the zero-emission vehicle (ZEV) market," the ICCT said in a press release as part of its third annual Global Automaker Rating on Tuesday.
BYD exceeded Tesla for the first time in 2024 in BEV (Battery Electric Vehicle) sales, the report says, while maintaining that both companies remain "leaders" in the ratings.
The report also says that the Chinese domestic market now accounts for over 11 million EVs sold annually, which is "more than half" of the total EV sales throughout the globe.
Why It Matters: The news comes in as BYD has been expanding its presence throughout multiple countries, with Europe currently <a href="https://www.benzinga.com/25/04/45097773/satellite-images-put-tesla-rival-byds-hungarian-factory-capable-of-producing-200k-units-annually-in-the-spotlight">a key area</a> for the Chinese EV giant.
The company recently launched its best-selling model in Europe, the Seagull EV, which would be called the <a href="https://www.benzinga.com/markets/25/05/45560953/byds-europe-pivot-in-full-swing-with-new-26000-affordable-ev-amid-tesla-sales-slump">Dolphin Surf EV </a>in the region for $26,000. This comes in as the automaker <a href="https://www.benzinga.com/25/04/44946809/byd-rejigs-european-strategy-amid-lack-of-market-knowledge-and-modest-dealer-network-report">overhauled its European strategy</a> after it failed to meet targets set when it entered the region.
On the other side of the coin, BYD has been <a href="https://www.benzinga.com/news/topics/25/06/45715047/byds-aggressive-pricing-triggers-ev-rat-race-stock-tumbles-authorities-voice-concern">facing criticism</a> over its aggressive discounts amid China's ongoing EV price war. The company recently released the <a href="https://www.benzinga.com/markets/tech/25/06/45855643/tesla-rival-byd-launches-15000-seal-06-sedan-as-chinas-ev-price-war-heats-up">Seal 06 EV</a> sedan in China, retailing for $15,000.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/06/45900203/xpeng-receives-10000-pre-orders-in-under-an-hour-for-new-tesla-model-3-rival-report">Xpeng Receives 10,000 Pre-Orders In Under An Hour For New Tesla Model 3 Rival: Report</a></li>
</ul>
Photo courtesy: Tada Images / Shutterstock

BYDDF

BYDDY

TSLA

Elon Musk Has A New Problem: BYD Beats Tesla In Global EV Sales Amid Europe Expansion

Markets

Press Releases

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

Management

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Health Care

General

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Comments

Vaxart

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL